scholarly journals Update Treatment of Male Androgenetic Alopecia

2021 ◽  
Vol 33 (1) ◽  
pp. 63
Author(s):  
Damai Trilisnawati ◽  
Sarah Diba ◽  
Yuli Kurniawati ◽  
Suroso Adi Nugroho ◽  
Rusmawardiana Rusmawardiana ◽  
...  
Keyword(s):  
Hair Loss ◽  
Self Esteem ◽  
Androgenetic Alopecia ◽  
Clinical Documentation ◽  
Prostaglandin Analog ◽  
Hair Transplantation ◽  
Hormonal Factors ◽  
European Consensus ◽  
Topical Minoxidil

Background: Male androgenetic alopecia (MAGA), also known as androgenetic alopecia, is the most common hair loss in males who have a genetic predisposition. The pattern of baldness in MAGA starts from the frontal area in a triangular pattern, followed by progressive thinning of the vertex until baldness occurs. Generally, the diagnosis of MAGA is established by clinical examination. FDA has approved a combination of topical minoxidil and oral finasteride for MAGA treatment. Currently, there is another treatment option like dutasteride, a prostaglandin analog, ketoconazole, and co-adjuvant therapy like laser therapy, hair transplantation, and so on. Purpose: To provide an updated treatment for MAGA. Review: Etiopathogenesis of MAGA is influenced by genetic susceptibility and hormonal factors. The European Consensus Group set the evaluation diagnosis of MAGA to include a historyof hair fall, physical examination, hair examination, supporting examination, and clinical documentation. There are therapeutic options for MAGA, including antiandrogen therapies, androgen-independent therapies, and co-adjuvant therapies. The FDA has approved a combination of topical minoxidil and oral finasteride for MAGA treatment. MAGA may affect patients’ quality of life and self-esteem. In general, patients expect higher. Conclusion: MAGA is the most common progressive hair loss in males. The MAGA therapy is expected to achieve cosmetically significant regrowth and to slow additional hair loss.

scholarly journals Investigating the Safety and Efficacy of Platelet-Rich Plasma (PRP) Treatment for Female Androgenetic Alopecia: Review of the Literature

Medicina ◽  
2021 ◽  
Vol 57 (4) ◽  
pp. 311
Author(s):  
Santo Raffaele Mercuri ◽  
Giovanni Paolino ◽  
Matteo Riccardo Di Nicola ◽  
Laura Vollono
Keyword(s):  
Hair Loss ◽  
Platelet Rich Plasma ◽  
Androgenetic Alopecia ◽  
Cochrane Central Register ◽  
Review Of The Literature ◽  
Psychosocial Burden ◽  
Female Pattern Hair Loss ◽  
Central Register ◽  
Topical Minoxidil

Background: female androgenetic alopecia (FAGA) is a common cause of non-scarring alopecia in women, affecting approximately 40% of women by age 50, bearing a significant psychosocial burden on affected patients. Platelet-rich plasma (PRP) has been widely investigated as a potential effective treatment for several dermatological conditions, including male androgenetic alopecia (MAGA). However, few studies have been conducted focusing on the use of PRP in FAGA. The aim of this review was to identify reports that investigated the use of PRP for the treatment of FAGA. Methods: Electronic databases of MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to September 2020 have been searched using different combinations of the following terms: “androgenetic alopecia,” “FAGA,” “female pattern hair loss,” “platelet-rich fibrin,” “platelet-rich plasma,” and “PRP”. Results and conclusions: Eight (n = 8) clinical studies consistent with our research were identified. A total of 197 subjects has been enrolled in the included studies. All of them were adult female patients (mean age: 38.9) affected by female pattern hair loss. PRP is a well-tolerated procedure which showed promising results in males-only and mixed populations of AGA patients. PRP showed to produce high levels of satisfaction and improvement in the quality of life in patients affected by FAGA. In the light of this evidence, PRP may be proposed in patients who did not respond or did not tolerate topical minoxidil, as well as in combination with topical and oral treatments.

scholarly journals The potential of androgenic alopecia management from plant derivatives

Food Research ◽  
2020 ◽  
Vol 4 (S2) ◽  
pp. 1-13
Author(s):  
N.M. Noor ◽  
N.Z. Nazri ◽  
N.A. Mohamad-Salam ◽  
Z.I. Abdul-Rasid ◽  
R. Hasham ◽  
...  
Keyword(s):  
Hair Loss ◽  
Hair Growth ◽  
Self Esteem ◽  
Androgenetic Alopecia ◽  
Depression And Anxiety ◽  
Androgenic Alopecia ◽  
Growth Cycles ◽  
Male Pattern Baldness ◽  
Male Pattern

Hair loss or alopecia is a common dermatological issue that can affect millions of human population of all ages and both gender, male and female. Frequently, alopecia has been found to be associated with significant adverse effects or reduction of psychological and self-esteem. Consequently, this may lead to psychological problems such as depression and anxiety, thus it may negatively impact the quality of life as well. There are several types of hair loss including androgenetic alopecia (AGA), alopecia areata (AA), alopecia totalis (AT), Alopecia Universalis (AU), cicatricial alopecia (CA), senescent alopecia (SA), traction alopecia (TA) and telogen effluvium. However, this review will focus on the androgenic alopecia only. Androgenic alopecia (AGA) also known as male pattern baldness is referred to as hair loss that often occurs in men after puberty caused by the androgen. In addition, this review will discuss on the hair growth cycles and their mechanism on the androgenic alopecia and lastly the management of androgenic alopecia using plant derivatives and methods used in order to prolong the efficacy of androgenetic alopecia treatment.

Application and Approach to Hair Transplantation in Females

1997 ◽  
Vol 14 (2) ◽  
pp. 137-141
Author(s):  
Paul C. Cotterill
Keyword(s):  
Treatment Option ◽  
Hair Loss ◽  
Androgenetic Alopecia ◽  
Hair Transplantation ◽  
New Techniques ◽  
Inflammatory Dermatosis ◽  
Viable Treatment

Hair transplantation for females has become a much more viable treatment option because of recent improvements in technique employing micrografts and minigrafts as well as multiple-strip donor harvesting. The author describes how these new techniques are applied to the various types of transplantation in women, such as for androgenetic alopecia, traction alopecia, eyebrows, inactive inflammatory dermatosis, hair loss, and postrhytidectomy scarring. “Pearls,” to emphasize the contrast in the approach to the treatment of women with that of their male counterparts and the importance of assessing for realistic expectations, are described. A review of 827 females seen in consultation over the last 10 years showed that 70% of women with androgenetic alopecia were candidates for hair transplants.

scholarly journals Expert opinion on current and emerging treatment options in androgenetic alopecia and telogen effluvium: an Indian perspective

2021 ◽  
Vol 8 (1) ◽  
pp. 152
Author(s):  
Bharat Lalwala ◽  
Siddhartha Das ◽  
Srinivasa Murthy ◽  
Abir Saraswat ◽  
U. R. Dhanalakshmi ◽  
...  
Keyword(s):  
Expert Opinion ◽  
Hair Loss ◽  
Treatment Options ◽  
Androgenetic Alopecia ◽  
Oral Medications ◽  
Choice Of Treatment ◽  
Topical Minoxidil ◽  
Current Scenario ◽  
Approved Drugs ◽  
The Individual

<p class="abstract">The diagnosis and management of hair loss needs an organized and systematic approach for recognizing pattern of hair loss and identification of hair loss etiology. Early and specific diagnosis is essential to initiate appropriate treatment in the early phases of hair loss. Topical minoxidil and oral finasteride are the only approved drugs for androgenetic alopecia (AGA). Various other treatment options are widely used but have limited clinical evidence. Similarly, there are no specific treatments recommended for telogen effluvium (TE). However, the treatment may become challenging with increasing availability of new formulations and drugs with no substantial evidence to support them. Multiple focused group discussions were conducted among Indian dermatologists to gain expert opinion on appropriate management of AGA and TE in the current scenario. This article summarizes the consensus clinical viewpoints for topical and oral medications, role of nutritional supplements, and other adjunctive therapies in managing AGA and TE. The panel highlighted that the choice of treatment for AGA and TE depends on the individual hair loss pattern and response to medications. A brief discussion on the use of shampoos and procedures has also been highlighted.  </p>

Asymmetry of the Receding Hairline in Men With Early Androgenetic Alopecia

2016 ◽  
Vol 20 (6) ◽  
pp. 546-549
Author(s):  
Reza Pashmineh Azar ◽  
Alexander Horst Thomas ◽  
Marcus Maurer ◽  
Gerd Lindner
Keyword(s):  
Hair Loss ◽  
Classification System ◽  
Quantitative Methods ◽  
Frontal Region ◽  
Androgenetic Alopecia ◽  
Hair Transplantation ◽  
Technical Improvement ◽  
Quick Assessment ◽  
Male Pattern

Background: The Norwood classification system is commonly used to ascertain the progress of androgenetic alopecia (AGA) with a robust and quick assessment, but it lacks precision in the frontal region, notably during the onset of male pattern hair loss. Objective: Due to the ongoing technical improvement in restorative hair transplantation practices, we aim to develop simple quantitative methods for measuring the progression of AGA. Methods: Here, we used a quantitative system to evaluate the progress of AGA of the frontal receding hairline in a case study with 41 patients. Results: We found subtle differences in the extent of frontotemporal regressions that were not captured by the Norwood classification system. The majority of patients exhibited significantly larger right-sided frontotemporal regressions. Conclusion: These results indicate that the quantification system used is a valuable tool in complementing the Norwood classification system to more precisely determine the recessing hairline characteristics in early stages of hair loss. Our findings also suggest that hairline regression in AGA-affected patients is asymmetrical, a hitherto unnoticed disorder-associated phenomenon with unknown biological causality.

scholarly journals Pharmacological therapeutics in androgenetic alopecia

2020 ◽  
Vol 63 (5) ◽  
pp. 277-285
Author(s):  
Doyoung Kim ◽  
Sujin Park
Keyword(s):  
Hair Loss ◽  
Treatment Options ◽  
Daily Intake ◽  
Androgenetic Alopecia ◽  
Men And Women ◽  
Reductase Inhibitors ◽  
Female Pattern Hair Loss ◽  
Evidence Quality ◽  
Topical Minoxidil ◽  
Current Guidelines

Androgenetic alopecia (AGA) is the most common type of hair loss and affects both men and women. Male pattern hair loss shows characteristic frontal recession and vertex baldness, whereas female pattern hair loss produces diffuse alopecia over the mid-frontal scalp. AGA is mediated by increased androgen susceptibility in affected scalp hairs. 5α-Reductase converts testosterone into dihydrotestosterone, a potent androgen, in the scalp. Both androgen receptors and 5α-reductase have higher expression levels in the balding scalp than in non-affected regions. Increased androgen susceptibility induces hair follicle miniaturization, which leads to the progressive loss of thicker terminal hairs in the balding scalp. Currently, topical minoxidil and oral 5α-reductase inhibitors, such as finasteride and dutasteride, are approved options for the pharmacological treatment of AGA. Topical minoxidil remains the mainstay of therapy for mild to moderate AGA in both men and women. The daily intake of 1-mg finasteride or 0.5-mg dutasteride shows better efficacy than topical minoxidil in regard to hair regrowth in male AGA. Anti-androgens can be used in female AGA wit clinical and biochemical evidence of hyperandrogenism. Patients may be overwhelmed and confused by the variety of treatment options for AGA management, including over-the-count drugs with low evidence quality. Therefore, physicians must be aware of the current guidelines for the management of AGA based on evidence-based approaches to select better options for patients.

scholarly journals Managing patterned hair loss – a hair raising task!

2021 ◽  
Vol 1 ◽  
pp. 55
Author(s):  
Aseem Sharma ◽  
Manasi Shirolikar ◽  
Madhulika Mhatre
Keyword(s):  
Hair Loss ◽  
Clinical Presentation ◽  
Short Review ◽  
Population Based ◽  
Androgenetic Alopecia ◽  
Psychosocial Burden ◽  
Weighted Averages ◽  
Female Pattern Hair Loss ◽  
Topical Minoxidil

Diffuse alopecia wields a significant psychosocial burden by virtue of its clinical presentation and visibility. Patterned alopecia is an umbrella term with the focus point being androgen-mediated alopecias - androgenetic alopecia/male pattern baldness/male androgenetic alopecia and female pattern hair loss/female androgenetic alopecia, both of which have a genetic susceptibility that alters the follicular sensitivity to circulating androgens. Diffuse alopecia affects nearly half the population based on weighted averages. It may present with hair shedding and hair thinning (miniaturization) or a combination. With the female variant, the role of androgens is not fully delineated; hence, the term female pattern hair loss which has replaced prior nomenclature. Managing patterned hair loss has seen a sea change in the last decade, moving well beyond the FDA-approved modalities - topical minoxidil and oral finasteride. Through this short review, the authors have attempted to condense existing information into a ready reference.

scholarly journals Hair transplantation in androgenetic alopecia

2021 ◽  
Vol 1 ◽  
pp. 20
Author(s):  
Kavish Chouhan ◽  
Gillian Roga
Keyword(s):  
Medical Therapy ◽  
Hair Loss ◽  
Androgenetic Alopecia ◽  
Hair Transplantation ◽  
Common Cause ◽  
The Past ◽  
Scarring Alopecia ◽  
Male Pattern

Androgenetic alopecia is the most common cause of non-scarring alopecia in men. Even though the past couple of years have seen significant advancements in the management of patterned hair loss. Medical therapy as a standalone treatment remains unsatisfactory and surgical restoration of hair has found to be extremely gratifying as far as male pattern hair loss is concerned. In this article, we will review the latest developments in the field of hair transplantation undertaken in androgenetic alopecia.

Sign in / Sign up

Export Citation Format

Share Document